[HTML][HTML] Mechanism of metabolic dysfunction-associated steatotic liver disease: important role of lipid metabolism

X Feng, R Zhang, Z Yang, K Zhang… - Journal of Clinical and …, 2024 - pmc.ncbi.nlm.nih.gov
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-
alcoholic fatty liver disease, has a high global prevalence and can progress to metabolic …

Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists

G Targher, A Mantovani, CD Byrne, H Tilg - Gut, 2025 - gut.bmj.com
Clinically effective pharmacological treatment (s) for metabolic dysfunction-associated
steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated …

Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis

MH Nielsen, J Nøhr-Meldgaard… - American Journal …, 2025 - journals.physiology.org
The choline-deficient l-amino acid defined-high-fat diet (CDAA-HFD) mouse model is widely
used in preclinical metabolic dysfunction-associated steatohepatitis (MASH) research. To …

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

O Kikuchi, Y Ikeuchi, M Kobayashi… - Journal of Diabetes …, 2024 - Wiley Online Library
Abstract Aims/Introduction Imeglimin is a recently approved oral antidiabetic agent that
improves insulin resistance, and promotes insulin secretion from pancreatic β‐cells. Here …

Quantification of 11 metabolites from quinoa seeds through HPLC-MS/MS and evaluation of their antidiabetic activities through molecular docking

L Qin, H Guo, Y Wang, X Hou, F Wu, H Du… - Journal of Food …, 2025 - Elsevier
This study extracted diverse active components from black, white, and red quinoa seeds with
an ethanol ultrasonic method. A high-performance liquid chromatography coupled with …

Advancements and Challenges in Understanding and Treating Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Focus on GLP-1 Agonists

E Hardy - jmsgr.tamhsc.edu
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known
as non-alcoholic fatty liver disease (NAFLD), poses a significant global health challenge …